Therefore, strategies that ‘boost’ T cell priming, or activation may promote enhanced T cell-mediated anti-tumor responses and improve responsiveness to anti-PD-1 or anti-CTLA-4 ICB8,9. This evidence concerns the gene CTLA4 and neoplasm.